Status:
TERMINATED
Trial of Endocrine Against Locoregional Therapy First in Postmenopausal Women With Early Breast Cancer
Lead Sponsor:
Danish Breast Cancer Cooperative Group
Collaborating Sponsors:
The Danish Medical Research Council
Danish Cancer Society
Conditions:
Operable Breast Neoplasms
Eligibility:
FEMALE
60+ years
Phase:
PHASE3
Brief Summary
The hypothesis to be addressed in this randomized phase III trial is that 4 months of letrozole may be superior to surgery as primary therapy for early stage hormone receptor positive breast cancer in...
Eligibility Criteria
Inclusion
- Informed consent
- Age 60 years or older
- Measurable non-metastatic and non-inflammatory breast cancer
- Tumor of 2 cm or larger
- ER and/or PgR positive tumor
- Co-morbidity index 0 - 3, e.g., no other serious medical condition
Exclusion
- Prior medical therapy for a malignant disease, including aromatase inhibitors
- Distant metastasis
- Need for chemotherapy
- Past or current history of other neoplasms (except for curative treated basal skin cancer or in situ carcinoma of the cervix uteri)
- Treatment with a non-approved drug within 30 days
Key Trial Info
Start Date :
May 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2013
Estimated Enrollment :
123 Patients enrolled
Trial Details
Trial ID
NCT00908531
Start Date
May 1 2009
End Date
December 1 2013
Last Update
April 29 2019
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Dept. of Breast Surgery; Aalborg Sygehus
Aalborg, Denmark, DK-9000
2
Dept. of Surgery; Århus Sygehus
Aarhus, Denmark, DK-8000
3
Dept. of Breast Surgery; Rigshospitalet
Copenhagen, Denmark, DK-2100
4
Dept. of Surgery; Sydvestjysk Sygehus Esbjerg
Esbjerg, Denmark, DK-6700